Introduction
Type 2 Diabetes management has come a long way from simply “controlling blood sugars.” Two drug classes, GLP-1 Receptor Agonists (Semaglutide, Liraglutide) and SGLT-2 Inhibitors (Empagliflozin, Dapagliflozin), have revolutionized modern pharmacotherapy for T2DM management. These agents have demonstrated impressive benefits for CV, Renal, and Weight outcomes, which extend far beyond blood sugar control, making it an absolute must-know for every PharmD student/pharmacist.
Key Differences
GLP-1 Receptor Agonists activate an incretin hormone that increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and enhances satiety. GLP-1s have impressive HbA1c lowering and weight loss, making it an excellent choice for obese T2DM patients. With the advent of Tirzepatide, a dual GIP/Glucagon-like peptide receptor agonist, this class has reached newer heights of efficacy.
SGLT-2 Inhibitors inhibit glucose reabsorption in the kidney, resulting in glucosuria with consequent osmotic diuresis. These agents have impressive benefits for patients with Heart Failure and CKD; in fact, Empagliflozin reduced CV mortality by 38% in the EMPA-REG OUTCOME trial.
Conclusion
Which of these two classes of drugs to use depends entirely on the comorbid conditions of the patient, GLP-1 for obese patients with maximum HbA1c reduction and SGLT-2 for heart failure and CKD. As pharmacists, we should stay updated about these classes of drugs, and that’s what makes all the difference in patient outcomes.
“Modern diabetes care is about protecting the heart and kidneys — not just the sugar levels.”
Quick Questions
Q1. Which of these two classes of drugs would you prefer in a patient with T2DM, HFrEF, and why?
Q2. What is Euglycemic DKA, and which drug class is associated with this side effect?
Q3. What was the name of the study that proved the cardiovascular benefits of Empagliflozin?